• Sandor is a senior life science consultant with deep expertise in cardiovascular and RNA-based therapeutics.

 

• As co-founder of Cardior Pharmaceuticals, he led the early development of miRNA inhibitors for heart failure, contributing to the company's acquisition by Novo Nordisk in 2024. His work has helped establish new paradigms for treating chronic heart disease through genetic pathway modulation.

​

• He has led preclinical cardiovascular and cardiometabolic modeling programs, advancing novel therapies from concept to clinic. His research in cardiovascular genomics—particularly the development of antisense oligonucleotides (ASOs) for heart failure—has been instrumental in progressing RNA-targeted therapies. 

​

• At Cardior, Sandor pioneered in vivo proof-of-concept studies in large animal models, demonstrating the clinical potential of RNA-based interventions to modulate cardiac pathways. His leadership in scientific due diligence and competitive analysis has supported strategic partnerships and M&A efforts across the biotech sector, with a focus on cardiovascular innovation. 

 

• Sandor also has a long and established academic career in cardiovascular physiology and pharmacology, which has provided a strong foundation for his translational research and therapeutic development efforts. He is member of the OSWG (Oligonucleotide Safety Working Group) and several scientific associations. With an H-index of 83 and over 130 peer-reviewed publications, he brings scientific rigor and strategic insight to the development of transformative genomic therapies.